The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.
Filter by category
- All
- Blog
- Congress
- Scientific resource
- Webinar
- Poster
- Scientific publication
- Press release
- Press coverage
- News
Filter by category
Scientific publication
03/11/2022
Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection
We investigated the efficiency of Vaccine Vector based on Chimpanzee Adenovirus in golden Syrian hamsters against SARS-Cov-2 infection. Learn more here.
Poster
01/11/2022
Translational pharmacology supporting biologics development in Oncology
Translational Pharmacology is responsible for connecting products of novel molecular research, such as Biologics, to the patients that need it. Learn more here.
Press release
19/10/2022
ERES IV acquires a majority stake in Oncodesign Services
ERES IV, advised by Elyan Partners, acquires a majority stake in Oncodesign Services and will file an offer on the company’s remaining shares. Find out more
Webinar
13/10/2022
Fragment-Based Drug Discovery — Hitting Targets Using the Right Chemistry and Expertise Alliances
Learn about Fragment-Based Drug Discovery (FBDD) and its Applications in our Webinar with leading experts from the field of FBDD.
Press release
30/09/2022
The General Meeting of Oncodesign authorises the allocation of OPM
Each Oncodesign shareholder will receive one OPM share for one ONCODESIGN share held
Press release
28/09/2022
Euronext Paris authorises the listing of OPM shares
Oncodesign Precision Medicine (OPM) and Oncodesign announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access + market in Paris of OPM’s ordinary shares.
Press release
26/09/2022
Servier exercises the exclusive worldwide license option of their collaboration program LRRK2
Servier and Oncodesign Precision Medicine (OPM) announce that Servier has exercised its exclusive license option for their drug candidate
Press release
22/09/2022
OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment
Global pharmaceutical group Servier and Oncodesign Precision Medicine (OPM) announce a collaborative research agreement
Poster
02/09/2022
Lewis acid catalyzed chemoselective and regioselective epoxide ring opening with sulfoximines
We report Sulfoximines with the first regioselective Epoxide Ring opening; these findings broaden their Drug Discovery and design applications. Read more.
Scientific publication
30/08/2022
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor Antagonist 177Lu-Satoreotide Tetraxetan and the Agonist 177Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours
Read now our new scientific publication focused on Anti-Tumour Activity!
Press release
01/07/2022
ONCODESIGN announces the separation of its two business lines – Service and Biotech
ONCODESIGN today announced that the Board of Directors has approved the subsidiarisation of its Biotech business.
Poster
29/06/2022
In vitro pharmacological profile of Compound A
Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease.